Memory T cells exhibit tremendous antigen specificity within the immune system and accumulate with age. Our studies reveal an antigen-independent expansion of memory, but not naïve, CD8 + T cells after several immunotherapeutic regimens for cancer resulting in a distinctive phenotype. Signaling through TCR or CD3 in both mouse and human memory CD8 + T cells markedly upregulated programmed death-1 (PD-1) and CD25 (IL-2 receptor alpha chain) and led to antigen-specific tumor cell killing. In contrast, exposure to cytokine alone in vitro or with immunotherapy in vivo did not up-regulate these markers but resulted in expanded memory CD8 + T cells expressing NKG2D, granzyme B and possessing broadly lytic capabilities.
Introduction
Memory T cells represent an arm of the adaptive immune system that are long-lived, and are capable of rapid antigen-specific responses. Memory T cells have been shown to have functional advantages over naïve T cells, as they develop more rapidly into cytolytic effector cells and produce greater amounts of cytokines after antigenic stimulation 1 . Although T cells classically require T cell receptor (TCR) engagement and proper co-stimulation for complete activation and proliferation, memory T cells have also been observed to proliferate in response to various cytokines during viral infections [2] [3] [4] [5] [6] . These "bystander cells" proliferate and gain effector functions in response to the cytokine milieu produced during the course of viral and bacterial infections in mice and humans [7] [8] [9] [10] . Cytokines alone can induce this as a single dose of recombinant type-I IFN resulting in a transient increase in the proliferation of CD8 + , CD62L + CD44 high memory T cells, which was independent of co-ligation of the TCR 11 . Such proliferation was not induced by the direct effects of type-I IFNs on CD8 + T cells, but was due to type-I IFN-driven production of secondary cytokines such as IL-15 4, 12 . Effector and memory CD8 + T cells express elevated levels of the receptors for IL-12 and IL-18, and secrete IFN-γ in response to stimulation with both cytokines 13 , suggesting other cytokine pathways also can induce their expansion. Similar to the secondary cytokine-driven proliferation observed after type-I IFN stimulation, IL-2, and toll-like receptor (TLR) agonists, e.g. CpG and Poly:IC, have also been described as having the capacity to induce bystander proliferation of CD8 + CD44 high T cells 12, 14, 15 . The extent of antigen-specific proliferation versus bystander expansion has been the subject of considerable debate and may be contingent on the pathogen model and tissue examined 9, 13, 16 . Cancer therapies that target the stimulation of the immune system via agonist antibodies, cytokine-based modalities, or TLR agonists have been shown to result in potent
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+ T cell-mediated anti-tumor effects 17, 18 . We have previously shown that a combination immunotherapy consisting of an agonist CD40 antibody and IL-2 results in synergistic antitumor effects 19 . Treatment of mice with other cytokine or TLR agonist combinations, such as
CpGs and IL-15 or IL-2 and IL-12, also resulted in marked anti-tumor effects 18 . In all of these models, the anti-tumor effects were associated with rapid, extensive CD8 + T cell expansion. The anti-tumor effects were dependent on CD8 + T cells, the production of IFN-γ and IL-12, and the expression of Fas ligand (FasL), but were independent of CD4 + T cells, NK cells and perforin expression 18, 19 . In the present study we sought to more completely characterize the CD8 + T cells expanded after cytokine immunotherapies and determine the role or need for antigen-specificity in their effector functions. Here we demonstrate that cytokine-mediated stimulation of memory CD8 + T cells results in antigen-nonspecific expansion, correlating with a unique phenotype that may also account for the dramatic anti-tumor effects observed as a cancer therapy, as well as providing insights as to their regulation.
Materials and Methods

Mice
C57BL/6 and BALB/c mice were purchased from the animal production area of the National Cancer Institute (NCI, Frederick, MD), or the Jackson Laboratories (Bar Harbor, ME).
Thymectomized mice received surgical thymectomy procedure by Charles River Laboratories at 6-8 weeks of age. OT-I C57BL/6 mice and wild-type controls were purchased from the Jackson Laboratory (Bar Harbor, ME) and were used at 8-24 weeks old. Mice were 8-16 weeks old and mouse studies were performed with the consent and approval of the University of Nevada, Reno, University of California, Davis, and NCI IACUCs. in the study after obtaining informed consents. Subjects were randomized in a 1:1 ratio to receive imiquimod 5% cream or vehicle cream (both supplied by 3M {later Graceway} Pharmaceuticals, Saint Paul, MN). Starting from day 0, subjects were instructed to apply the cream (250 mg) once daily over the affected area for 14 days. On the day of surgery (day 14), subjects then underwent wide excision of the tumor and sentinel lymph node biopsy. Samples from the excised tumors were fixed in 10% formalin and processed with standard paraffin techniques.
Immunohistochemistry
Serial sections of skin from the paraffin-embedded blocks were obtained for IHC and evaluated for infiltration of immune cells. Sections were stained using the UltraVision LP Detection System HRP Polymer, and were stained for CD8 (Clone SP16) and CD25 (Clone 4C9), and were counterstained with Methyl Green (Thermo Fisher Scientific, Fremont, CA).
Human and Mouse T cell cultures
2x10
6 mouse splenocytes were cultured in 6-well plates (Greiner, Germany) with anti-CD3/anti-CD28 or rhIL-2 for 3 days prior to analysis by flow cytometry. Human leukocytes were flushed 
Results
Memory CD8 + T cells markedly expand in vivo after successful systemic cancer immunotherapy regimens
Consistent with previous studies, we treated mice with anti-CD40 plus IL-2 and observed were proliferating in the absence of naïve T cell conversion, thymectomized mice, which have a finite naïve pool, were treated with immunotherapy. We observed that the total numbers of naïve CD8 + T cells remained unchanged 11 days after immunotherapy in both the thymectomized and control mice ( Figure 1D ) and we observed that the effector/memory CD8 + T cells from both control and thymectomized mice significantly expanded 11 days after immunotherapy ( Figure   1E ). The data showed that only the memory pool was altered after immunotherapy as the total naïve population was not changed. The selective expression of CD122 on the memory but not naïve T cells is likely to give them an advantage in cytokine-only environments 22, 23 . Nearly all CD44 high CD8 + T cells expressed CD122, even in resting animals as opposed to the naïve CD8 + T cells ( Figure 1F ). These results suggest an antigen-nonspecific expansion of memory CD8 + T cells was occurring after successful systemic immunotherapy.
Cytokine immunotherapy-expanded memory CD8+ T cells lack surface molecules indicative of recent TCR ligation, but upregulate the expression of effector molecules
Because we have previously shown CD8 + T cells to be responsible for the anti-tumor effects 19 , we next sought to further phenotypically characterize the expanded CD8 population.
Interestingly, the expanded CD8 + T cells were negative for CD25, which is associated with TCR triggering, but a significant proportion of CD8 + T cells were NKG2D + in both the lymph nodes and the spleen (Figure 2A ,B Figure S1B ).
Lack of CD25 upregulation suggested activation independent of TCR engagement. To further support this observation, we looked at expression of another molecule associated with TCR engagement, programmed death-1 (PD-1). PD-1 is highly expressed (>50%) on both CD4 + and CD8 + T cells following TCR crosslinking 24 and its prolonged expression both in vitro and in vivo during chronic inflammation has been correlated with immunosuppression and an exhausted phenotype [25] [26] [27] [28] [29] . In addition to TCR engagement, PD-1 upregulation has also been documented following stimulation with common gamma chain cytokines such as IL-2, although to a much lesser extent (~15-20%) 30 . Interestingly, signaling through PD-1 in the latter situation seemed to not interfere with cytokine induced T cell activation as PD-1 mediated inhibition of T cell effector functions has been well documented to occur after TCR engagement. Consistent with Figure 2D ). These results indicate that cytokine-based stimulation results in a markedly different phenotype on the memory CD8 + T cell population.
CD8 T cells displaying a TCR independent activation phenotype are broadly lytic, present intratumorally, and recognize tumor targets in part through NKG2D
In addition to a TCR independent activation phenotype, a large percentage of the expanded CD8 + T cell population expressed granzyme B after immunotherapy ( Figure 3A ). To determine the lytic capabilities of CD8 + T cells following immunotherapy, we performed antibody-redirected lysis assays. The in vivo expanded CD8 + T cells were cytolytic towards tumor targets ( Figure 3B ). To determine whether antigen-nonspecific T cells were capable of mediating anti-tumor effects in vivo, OT-I mice bearing the ova-negative 3LL lung carcinoma tumor were then treated with immunotherapy. The tumors grew significantly faster in OT-I control mice compared to
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From WT recipients, which may be due to the total T cell number deficits reported in these mice 43 as well as the absence of potential tumor-specific T cell responses ( Figure 5D ). Nonetheless, we observed significant anti-tumor effects in the OT-I mice treated with cytokine immunotherapy, suggesting that antigen specificity (in that over 90% of the entire T cell repertoire is directed to an antigen not present on the tumor) was not mandatory for anti-tumor effects of the T cells ( Figure 5D ). Together, these data demonstrate that antigen-specific triggering of CD8 
Human memory CD8 + T cells show a phenotype similar to mouse T cells after antigennonspecific stimulation both in vitro and in vivo
We next sought to determine if this expansion of CD25 -CD8 + memory T cells also 
Discussion
The findings presented herein demonstrate that memory CD8 + T cells can be a source of adaptive or innate effectors after cancer therapies depending on whether TCR or cytokine-alone triggering has occurred, using a process remarkably conserved across the species. It is striking that both mouse and human CD8 + T cells exhibit a phenotypically similar pattern both in vitro and in vivo. Bystander expansion of memory CD8 + T cells has been well documented in mouse virus infection models, but has not been as established in cancer immunotherapy models nor has the phenotype been carefully examined. The success of various immunotherapeutic regimens such as TLR agonists or cytokine-based regimens with advanced tumor models may therefore lead to antigen non-specific expansion of memory CD8 + T cells, which represent the primary effector mechanism.
To date, the vast majority of immunotherapeutic regimens used in cancer have focused on the goal of developing of tumor-specific responses by CD8 + T cells. This is highly desirable because it would allow for the generation of specific anti-tumor immunity and therefore be less likely to damage healthy tissues. However, due to the intrinsic nature of human cancers, the long-term efficacy of such an approach clinically may be limited due to the significant efforts of the tumor itself to avoid immune recognition and attack and the limited presence of sufficiently immunogenic tumor-associated and tumor-specific antigens. Down-regulation or loss of potential antigens present on the tumor, but not necessary for its survival, has occurred in numerous clinical scenarios and represents a significant hurdle with antigen-specific approaches 44, 45 . Our results suggest that memory T cells can exert antigen-nonspecific effects and these can be successfully exploited under the conditions of cytokine-based cancer immunotherapies.
The unique phenotype of theses T cells has not been reported but fits with the concept of the "two-signal" model for T cell activation. Memory T cells represent immune cells that have undergone at least two rounds of antigen selection (within the thymus and the periphery) and thus can be considered "safer" for antigen-nonspecific expansion. Memory cells express CD122
to a much greater extent than naïve T cells, which accounts for their proliferative advantage for cytokine alone-driven processes. Furthermore, the lack of the high affinity IL-2 receptor complex on these bystander cells indicates that continuously high levels of cytokines are needed for their expansion and survival. In contrast, when encountering antigen, the upregulation of CD25 gives the specific responders the advantage in a cytokine-limited environment for sustained responses.
In addition to CD25, we also investigated expression of another molecule associated with TCR engagement, PD-1 24 . PD-1 functions to suppress the immune response following activation [25] [26] [27] and its prolonged expression such as occurs with chronic inflammation has been correlated with an exhausted phenotype 28, 29 . In the context of cancer, the ligation of PD-1 on the surface of tumor-infiltrating T cells has been shown to induce anergy in those cells 46 . P<0.05, ** P<0.01, *** P<0.001.
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